Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (C...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Oncol
Main Authors: Shoushtari, Alexander N., Friedman, Claire F., Navid-Azarbaijani, Pedram, Postow, Michael A., Callahan, Margaret K., Momtaz, Parisa, Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2017
Fag:
Brief Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833656/
https://ncbi.nlm.nih.gov/pubmed/28817755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2391
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker